Sanofi is aiming to sign an agreement this weekend to sell control of its consumer health business to Clayton Dubilier & Rice, following a last-ditch attempt by a rival bidder to derail the deal ...

which align with our commitment to advancing transformative therapies for unmet medical needs.” Julien Dodet President of the Governing Board, Orano Med “Sanofi’s partnership with Orano Med ...

Sanofi confirmed on Monday plans to sell a controlling stake in its over-the-counter unit to a US investment fund, after employment and investment guarantees relieved political controversy. The ...

Fitch Solutions has predicted that the naira would slide to as low as N1,993 per dollar in 2028, severely impacting Nigeria’s ...

Sanofi is paying about $325 million to take a 16% stake in ... The agency expanded the approval of Novocure’s Optune electrical field medical device to include the treatment of metastatic non-small ...

Sanofi pitched today’s announcement in the context of its move last month to pay Orano Med and its partner RadioMedix 100 million euros upfront and commit up to 220 million euros in sales ...

Ahead of World Diabetes Day, Doctors Without Borders (MSF) called on pharmaceutical corporations Eli Lilly, Novo Nordisk, ...

Sanofi is putting down $18 million across three historically Black medical schools as part of the French pharma's efforts to boost clinical trial diversity. The 10-year investment will go to ...

Sanofi SAN-0.92%decrease; red down pointing triangle is in discussions with the French government to address concerns officials raised about a potential sale of a controlling stake in the company ...

Sanofi and Sudair Pharma Company (SPC ... NUPCO is the Unified Procurement Company for medical devices, pharmaceuticals, and medical supplies in the Kingdom of Saudi Arabia, wholly owned by the Public ...

PARIS, Oct 16 (Reuters) - French unions have called on workers at Sanofi (SASY.PA), opens new tab to strike from Thursday to protest a planned sale of the pharmaceutical group's consumer health ...

But Sanofi said efforts will focus on difficult-to-treat cancers, both hematological malignancies and solid tumors that have critical unmet medical need, including rare cancers such as multiple ...